Navigation Links
Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
Date:9/25/2011

ributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets innovative prescription drugs used to treat a number of diseases and conditions, including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease and respiratory. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, consumer health products, preventive vaccines and diagnostic tools. Novartis is the only company with leading positions in these areas. In 2010, the Group's continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 121,000 full-time-equivalent as
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- According to the new research ... Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), Applications (Pediatric, Musculoskeletal) ... Forecast to 2019" published by MarketsandMarkets, the global Physiotherapy ... by 2019 from $14,240.0 Million in 2014, at ... Browse 74 market data tables and ...
(Date:9/19/2014)... STATION, N.J. , Sept. 19, 2014 Merck (NYSE: ... United States and Canada , is ... Desafiando La Diabetes: Logra Tus Metas , an educational program ... their blood sugar -- a key treatment goal to help reduce ... United States are at a higher risk for developing ...
(Date:9/19/2014)... 19, 2014 Five MinuteClinic walk-in medical clinics are opening ... metropolitan area. Three clinics opened in Memphis ... clinic will be added in Springfield on ... is expected to open October 22.  MinuteClinic is the largest ... the United States . The Memphis ...
Breaking Medicine Technology:Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3
... Md., Oct. 19, 2011 /PRNewswire-iReach/ -- Precision Antibody™ ... Drug Administration (FDA) to develop monoclonal antibodies to influenza virus ... be used for in vitro assays to develop new vaccine ... production contract is for one year with the option of ...
... Oct. 19, 2011 Sharon Ladin, director of ... issued the following statement regarding the bipartisan, bicameral ... by Sen. Richard Blumenthal (D-Conn.) and Sen. Bob ... H.R. 2182 and contains provisions to incentivize the ...
Cached Medicine Technology:FDA Awards Precision Antibody Contract to Develop Monoclonal Antibodies for Influenza Vaccine Potency Assays 2FDA Awards Precision Antibody Contract to Develop Monoclonal Antibodies for Influenza Vaccine Potency Assays 3
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- U.S. military ... risk of skin cancer, according to a new study. ... serving abroad, researchers revealed. In some cases, military personnel ... in the color, shape or size of their moles ... can be risk factors for skin cancer, the study ...
(Date:9/19/2014)... By Alan Mozes ... (HealthDay News) -- Cancer patients burdened by stress and ... for complications following their operation, a new study suggests. ... "deficit" appeared to have a nearly three times greater ... or good quality of life. "We,ve long known ...
(Date:9/19/2014)... PA (PRWEB) September 19, 2014 "I ... fear getting wrinkles due to stretching the skin around ... Anniston, Ala. "This inspired me to design a more ... EYE CONTACT LENS SYSTEM provides a quicker, easier, more ... the need to perform this task manually, saves time ...
(Date:9/19/2014)... Mayo Clinic have discovered a defect in a key ... toxic protein in the brains of Alzheimer,s disease ... neurons both significant contributors to this type of ... Neuron , offers the potential that ... rescue this pathway," says the study,s lead investigator, ...
(Date:9/19/2014)... 19, 2014 Recently, Top10BestSEOHosting.com has ... that JustHost, IX Web Hosting and Bluehost are ... “As is known to most people, VPS (Virtual ... physical server computer into many servers, each of ... on someone’s own dedicated computer,” the manager of ...
Breaking Medicine News(10 mins):Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:Mayo researchers reveal pathway that contributes to Alzheimer's disease 2Health News:Top10BestSEOHosting.com: JustHost is One of the Best VPS Suppliers in 2014 2
... of Eating Disorders More at Risk for ,Pregorexia,PHOENIX, Jan. ... and Anxiety Disorders ( www.remudaranch.com ), the nation,s leading ... to look perfect while pregnant. "With the media giving ... pressure to look perfect and thin during pregnancy," said ...
... DIEGO, Jan. 19 NexBio announces the completion of ... drug candidate for influenza. The single-dose, escalating Phase I ... DAS181 safety in healthy subjects. The study drug ... is a novel broad-spectrum drug candidate for prophylaxis and ...
... Discusses the Impact of the Economic Crisis on Hospitals and ... A new report released today from the Noblis Center ... providers, has found that hospitals and health systems across the ... unprofitable healthcare services as a result of the economic crisis. ...
... The senior care marketplace is,booming, and so is the ... older Americans. In response, SeniorCareMarketer.com has released a new,eBook ... from the,competition. , The complimentary ... of,Senior Care Products and Convert Them to Leads" -- ...
... whole grains, , , MONDAY, Jan. 19 (HealthDay News) -- When ... by giving the children food they like. , That,s one ... issue of the Journal of the American Dietetic Association ... lunches didn,t have enough fruits and vegetables, and that one ...
... in design fuels The Amazing Heat Pack by Comfort ... affordable and renewable instant pain relief for athletes, arthritics, ... from painful joints and musclesBURLINGTON, Ontario, Jan. 19 ... such a groundbreaking first aid product been released as ...
Cached Medicine News:Health News:Remuda Ranch Reports More Women Seek to Be Thin During Pregnancy 2Health News:NexBio Completes First-in-Man Clinical Trial With DAS181 (Fludase(R)) and Strengthens Clinical Leadership 2Health News:NexBio Completes First-in-Man Clinical Trial With DAS181 (Fludase(R)) and Strengthens Clinical Leadership 3Health News:NexBio Completes First-in-Man Clinical Trial With DAS181 (Fludase(R)) and Strengthens Clinical Leadership 4Health News:Hospitals and Health Systems to Cut Back on Both Capital Spending and Unprofitable Services in 2009 2Health News:Hospitals and Health Systems to Cut Back on Both Capital Spending and Unprofitable Services in 2009 3Health News:Hospitals and Health Systems to Cut Back on Both Capital Spending and Unprofitable Services in 2009 4Health News:New eBook Helps Senior Care Suppliers Stand Out in Fast-Growing Marketplace 2Health News:Preschool Lunch Doesn't Always Pack Nutritious Punch 2Health News:Preschool Lunch Doesn't Always Pack Nutritious Punch 3Health News:The Amazing Heat Pack: The Most Innovative First Aid Solution Since the Band-Aid 2
... is a mechanical catheter intended to percutaneously ... access grafts. The disposable catheter requires no ... spiral shaft which extends beyond the 6F ... tip. In use, the tip spins to ...
... HYDROLYSER Percutaneous Thrombectomy Catheter is ... for rapid, effective and easy removal ... shunts. The HYDROLYSER catheter provides an ... thrombolytic therapy. ,Compatible with ...
Introduced more than 30 years ago by Dr. Thomas J. Fogarty, these embolectomy catheters are indicated for the removal of fresh, soft emboli and thrombi from vessels in the arterial system....
... The AVX catheter is designed to ... 12mm. High-pressure saline jets travel backwards ... to create a low pressure zone ... drawn into the catheter where it ...
Medicine Products: